Laboratory of Neuroendocrinology


jacqueline-kelly-PeUJyoylfe4_0  helloquence-OQMZwNd3ThU_0  sarah-shaffer-O3gOgPB4sRU_0

Uliana Tsoi, MD, PhD
Head of Laboratory

Research objectives

  • Clinical and molecular genetic characteristics of pituitary, adrenal and neuroendocrine tumors, as well as CVD during these disorders
  • Prognostic factors to predict transsphenoidal surgery effect in the treatment of hormone-active pituitary adenomas
  • Response markers and resistance to drug therapy in acromegaly patients
  • Diagnostic modalities of PET/CT for neuroendocrine tumors
  • Molecular genetic predictors of endocrine tumors in children and adults
  • Automated decision support system for the choice of treatment tactics in amiodarone-induced thyrotoxicosis

Training and education

Professional advanced training courses on the «Topical issues of neuroendocrinology», «Adrenal gland diseases» and residency programme in «Endocrinology». Lectures for endocrinologists at the Postgraduate Education Department of the Medical Education Institute of Almazov Centre. Supervision of students in clinical residency.

Clinical activities

The specialists of the Laboratory provide consultations, diagnostic and treatment services to the patients at the Diagnostic Centre and endocrinology units of Almazov Centre.

Participation in State Assignments

Specialists of the Laboratory develop the following topics of the state assignments:

  • Molecular and genetic characteristics of pituitary tumors and their influence on cardiovascular morbidity and mortality (supervised by E. Grineva, 2012—2014).
  • Molecular and genetic factors affecting the clinical course and therapy results in pituitary, thyroid and adrenal gland diseases (supervised by E. Grineva, 2015—2018).
  • Molecular and genetic predictors of endocrine tumors in children and adults (supervised by E. Grineva, 2016—2018).
  • Automated decision support system for the choice of tactics in amiodarone-induced thyrotoxicosis (supervised by E. Grineva, 2018—2020).


Personalized therapy for obesity and type 2 diabetes mellitus reducing CVD risks
Grant of the Russian Science Foundation: Grant Agreement No. 17-75-30052.
(supervised by Shlyakhto E., completion 31.12.2020)

The Laboratory experts participate in the research work for the development and creation of IT system for choosing personalized therapy for type 2 diabetes mellitus.


Patent No. 2699218 issued on 03.09.2019, application No. 2018135814 dated 09.10.2018.
«Method for diagnosing of MRI-negative ACTH-producing pituitary adenomas»
Authors: Tsoi U., Ryzhkova D., Cherebillo V., Dalmatova A., Belousova L., Kuritsyna N., Paltsev A., Ryzhkov A., Grineva E.



Уведомляем вас, что в соответствии с Федеральным законом от 06.03.2006 № 35-ФЗ «О противодействии терроризму» в Центре Алмазова введен комплекс дополнительных мер по безопасности, направленный на предотвращение террористических актов. В целях обеспечения безопасности граждан и целостности объектов инфраструктуры при посещении Центра Алмазова проводится дополнительный личный осмотр, осмотр вещей и автотранспорта. Отказ от соблюдения мер по безопасности может послужить причиной недопуска на территорию Центра Алмазова. Просим с пониманием отнестись к введенным мерам по безопасности.

С уважением, Администрация Центра Алмазова